Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
Merck licenced xevinapant from Debiopharm International in 2021 in a deal worth $1.08bn. Image Credit: Anne Czichos / Shutterstock Merck KGaA (Merck) has discontinued the
Merck licenced xevinapant from Debiopharm International in 2021 in a deal worth $1.08bn. Image Credit: Anne Czichos / Shutterstock Merck KGaA (Merck) has discontinued the
On the occasion of International Women’s Day (IWD), BGI Genomics interview Wang Leilei, a trailblazing blind model, and Viktoriya Tsay, an Uzbek advocate of women’s
After a decade at the helm, Nancy Simonian will depart Syros Pharmaceuticals as the biotech works through a pivotal cancer study and adjusts after losing